Ascendis Pharma AS
$ 234.99
0.02%
24 Feb - close price
- Market Cap 14,421,304,000 USD
- Current Price $ 234.99
- High / Low $ 237.00 / 229.11
- Stock P/E N/A
- Book Value -3.14
- EPS -4.44
- Next Earning Report 2026-05-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -8.18 %
- 52 Week High 242.00
- 52 Week Low 124.06
About
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Analyst Target Price
$283.08
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-12 | 2024-11-14 | 2024-09-03 | 2024-05-02 | 2024-02-07 | 2023-11-07 | 2023-09-05 | 2023-04-27 |
| Reported EPS | -0.55 | -1 | -0.64 | -1.58 | -0.64 | -1.72 | -2.11 | -2.3 | -1.54 | -2.88 | -2.16 | -1.98 |
| Estimated EPS | -0.1012 | -0.28 | -1.31 | -1.51 | -0.93 | -1.49 | -1.46 | -1.5 | -2.03 | -2.38 | -2.59 | -2.66 |
| Surprise | -0.4488 | -0.72 | 0.67 | -0.07 | 0.29 | -0.23 | -0.65 | -0.8 | 0.49 | -0.5 | 0.43 | 0.68 |
| Surprise Percentage | -443.4783% | -257.1429% | 51.145% | -4.6358% | 31.1828% | -15.4362% | -44.5205% | -53.3333% | 24.1379% | -21.0084% | 16.6023% | 25.5639% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-27 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.5134 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASND
2026-02-23 21:35:02
Ascendis Pharma A/S announced its Annual General Meeting for March 23, 2026, and released its 2025 annual report and Sustainability and P-ESG Report. Despite profitability challenges, the Danish pharmaceutical company reported a 127.7% return over the past year. The article also touches on related industry news concerning MP Materials and U.S. critical minerals policy.
2026-02-23 21:29:56
Ascendis Pharma (ASND) has scheduled its 2026 annual general meeting for March 23 in Copenhagen. Shareholders will review the company's 2025 performance, approve financial reports, and vote on carrying forward a €228 million loss, board elections including a new member, Deloitte's appointment as auditor, and expanded share buyback authority. A recent analyst rating on ASND stock is a Buy with a $256.00 price target, though TipRanks' AI Analyst "Spark" gives it a Neutral score due to balance sheet risk and unprofitable earnings despite improving fundamentals.
2026-02-23 19:52:56
Ascendis Pharma reported strong Q4 and full-year 2025 revenue growth driven by global expansion of Yorvipath and Skytrofa, reaching €248 million and €720 million respectively, despite negative currency impacts and operating expenses leading to a net operating loss for the full year. The company anticipates significant long-term growth with less than 5% market penetration for Yorvipath in the US and remains confident in upcoming regulatory decisions for TransCon CNP, while reiterating its Vision 2030 target of at least €5 billion in annual product revenue. Financial outlook for 2026 includes an expected operating cash flow of around €500 million, excluding potential TransCon CNP contributions, as Ascendis continues to invest in pipeline expansion and global market penetration.
2026-02-23 19:18:08
Ascendis Pharma A/S (ASND) shows significant growth potential in the biotech sector with a market cap of $13.81 billion, driven by its innovative TransCon technology and pipeline addressing rare endocrine disorders and oncology. Analysts are unanimously bullish, setting an average target price of $283.38, indicating a 25.95% upside. Despite not yet being profitable, the company's strong revenue growth and free cash flow underscore its financial resilience and strategic positioning for long-term growth.
2026-02-23 07:09:32
This article analyzes Ascendis Pharma A/s (NASDAQ: ASND) volatility using AI models to suggest trading strategies. It highlights a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias, noting current support testing and a favorable risk-reward setup. Three distinct strategies are presented for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
2026-02-20 09:52:15
Ascendis Pharma (NASDAQ:ASND) nearly doubled its total revenue to €720 million in 2025, driven by strong adoption of its endocrinology products like YORVIPATH (€477M) and SKYTROFA (€206M). Despite a full-year net loss of €228 million due to commercial investments, the company ended the year with a solid cash position and is anticipating FDA approval for TransCon CNP. Their success is attributed to the proprietary TransCon tech platform, which converts existing drugs into long-acting, once-weekly prodrugs, giving them a dominant market share in the US long-acting growth hormone market.
